Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.14), $0.04 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $40.6 million versus the consensus estimate of $41.46 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $175-200 million, versus the consensus of $184.4 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.